Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 9, 2012, Pages 593-599

  Gupta, Santosh K ^a   Singla, Suhas ^a   Bal, Chandrasekhar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Radionuclide peptide therapy; Renal toxicity

Indexed keywords

CREATININE; PENTETATE TECHNETIUM TC 99M;

ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; IN VITRO STUDY; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY;

FEMALE; HEMATOLOGIC DISEASES; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; RADIATION INJURIES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE;

EID: 84868286471     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1195     Document Type: Article

References (45)

1. Oyen WJ, Bodei L, Giammarile F, et al. Targeted therapy in nuclear medicine-current staus and future prospects. Ann Oncol 2007;18:1782.
2. Patel YC, Greenwood MT, panetta R, et al. The somatostatin receptor family [review]. Life Sci 1995;57:1249.
3. Bruns C, Weckbecker G, Raulf F, et al. Characterization of somatostatin receptor subtypes [review]. Ciba Found Symp 1995;190:89.
4. Reubi JC, Korner M, Waser B, et al. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004;31:803.
5. Roel Wierts, de point CD, Brans B, et al. Dosimetry in molecular nuclear therapy. Methods 2011;55:196.
6. Roberson PL, Buchsbaun DJ. Reconciliation of tumor dose response to external beam radiotherapy with 131-Iodinelabeled antibody for a colon cancer model. Cancer Res 1995; 55(suppl 23):5811s.
7. Zeng ZC, TangZY, Yang BH, et al. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1657.
8. Wessels BW, Meares CF. Physical and chemical properties of radionuclide therapy. Semin Radiat Oncol 2000;10:115.
9. Carlsson J, Forssell-Aronsson E, Glimelius B, et al. Therapy with radiopharmaceuticals. Acta Oncol 2002;41:623.
10. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analogs [177Lu-DOTA0,Tyr3]octreotatein patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754.
11. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17:R53.
12. de Jong M, Valkema R, Jamar F, et al. Somaostatin receptortargeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002;32:133.
13. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610.
14. Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2004;31:1038.
15. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46(suppl 1):62S.
16. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: Empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm 2002; 17:445.
17. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219.
18. Kwekkeboom DJ, de Harder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177-Lu-DOTA0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124.
19. Cwikla JB, Sankowski A, Seklecka N, et al. Efficacy of radionuclide treatment DOTAATTE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): A phase II study. Ann Oncol 2010;21:787.
20. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptortargeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptorexpressing malignancies. Semin Nucl Med 2002;32:97.
21. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response - Implications for radionuclide therapy. J Nucl Med 2008;49:1884.
22. Sierra ML, Agazzi A, Bodei L, et al. Lymphatic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer Biother Radiopharm 2009;24:659.
23. Valkema R, Pauwels S, Kvols LK, et al. long-term follow-up renal function after peptide receptor radiation therapy (PRRT) with [90Y-DOTA0,Tyr3] octreotide and [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med 2005;46:83S.
24. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTANOC) in the treatment of neuroendocrine tumors: A clinical phase II study. Am Oncol 2001;12:941.
25. Bernard BF, Krenning EP, Breeman WA, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929.
26. de jong M, Krenning EP. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43:617.
27. Das T, Chakraborty S, Banerjee S, et al. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor. Appl Radiat Isot 2007;65:301.
28. Siegel JA, Thomas SR, Stubbs JB. MIRD Pamphlet 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S.
29. Stabin MG. MIRDOSE: Personel computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538.
30. Russell CD, Bischoff PG, Kontzen FN, et al. Dubovsky measurement of glomerular filtration rate: Single injection plasma clearance method without urine collection. J Nucl Med 1985;26:1243.
31. Waller DG, Keast CM, Fleming JS, et al. Measurement of glomerular filtration rate with technetium-99m DTPA: Comparison of plasma clearance techniques. J Nucl Med 1987;28:372.
32. World Health Organization. WHO toxicity grading scale for determining the severity of adverse events. Available at: www.icssc.org/Documents/Resources/ AEManual2003Appen dicesFebruary062003%20final.pdf. Accessed 29 June 2008.
33. Nicolas G, Giovacchini G, Müller-Brand J, et al. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin N Am 2011;40:187.
34. Rolleman EJ, Kooij PM, de Herder WW, et al. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging 2007;34:1854.
35. Grudzinski JJ, Burnette RR, Weichert JP, et al. Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape. Cancer Biother Radiopharm 2010;25:417.
36. Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9.
37. Jamar F, Barone R, Mathieu I, et al. 86Y-DOTA0-DPhe3-Tyr-octreotide (SMT487): A phase I clinical studypharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510.
38. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labeled somatostatin analogue. Br J Cancer 1993;67:1437.
39. Bodei L, Cremonesi M, Zoboli S, et al. receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study, Eur J Nucl Med Imaging 2003;30:207.
40. Shimizu A, Kitamura H, Masuda Y, et al. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 1997;151:1231.
41. Statland BE, Winkel P, Bokelund H. Factors contributing to intra-individual variation of serum constituents. 2. Effects of exercise and diet on variation of serum constituents in healthy subjects. Clin Chem 1973;19:1380.
42. Cassady Jr. Clinical radiation nephropathy. Oncol Biol Phys 1995;31:1249.
43. Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and toxicity rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S.
44. Villard L, Romer A, Marincek N, et al. Cohort Study of somatostatin-based radiopeptide therapy with [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC plus [177Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012;30:1100.
45. Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study. Eur J Nucl Med Mol Imaging 2011;38:2125.